Bluejay Diagnostics
BJDX | NASDAQ
$2.29
-$0.32 (-12.26%)
At close: Nov 16, 2026, 4:00 PM ET
$2.29
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Bluejay Diagnostics Company Profile
Company profile explainedCompany Profile
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Indranil Dey | Principal Financial, Accounting & Executive Officer, President, Chief Executive Officer and Director |
| Kevin Vance | Chief Commercial Officer |
| Mark W. Feinberg | Chief Medical Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 04, 2026 | 8-K | Current Report |
| Oct 13, 2026 | 8-K | Current Report |
| Oct 06, 2026 | 8-K | Current Report |
| Sep 08, 2026 | 8-K | Current Report |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
Bluejay Diagnostics
| Country | United States |
| IPO Date | Nov 10, 2021 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Indranil Dey |
Contact Details
360 Massachusetts Avenue Acton,
Massachusetts 01720 United States
Stock Details
| Ticker Symbol | BJDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001704287 |
| CUSIP Number | 095633707 |
| ISIN Number | US0956337077 |
| SIC Code | 3841 |
Recent News
- 1 month ago / benzinga.comBluejay Diagnostics Advances Rapid Biomarker Testing For Sepsis Patients
- 2 months ago / globenewswire.comBluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets
- 3 months ago / globenewswire.comBluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization
Add to Watchlist
Select watchlists to add or remove BJDX